Bumrungrad International Hospital
| タイ | トルコ | オーストリア | |
| 肺癌手術 | から $18,000 / 612,000฿ | から $17,000 / 578,000฿ | から $42,000 / 1,428,000฿ |
| 肺摘出術 | から $26,000 / 884,000฿ | から $10,872 / 369,648฿ | から $50,000 / 1,700,000฿ |
| 定位放射線手術 | から $10,000 / 340,000฿ | から $4,500 / 153,000฿ | から $17,000 / 578,000฿ |
| 大腸癌に対する放射線療法 | から $5,500 / 187,000฿ | から $7,000 / 238,000฿ | から $12,000 / 408,000฿ |
| 乳癌化学療法 | から $3,000 / 102,000฿ | から $1,200 / 40,800฿ | から $15,000 / 510,000฿ |
Bookimedは肺癌ステージ4治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。肺癌ステージ4治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。肺癌ステージ4治療の旅路でお一人になることはありません。
Stage 4 lung cancer treatment in Thailand focuses on personalized medicine through molecular testing and multimodal therapies. Patients access targeted therapy, immunotherapy, and chemotherapy at JCI-accredited facilities. Advanced radiation techniques like 4D-VMAT and stereotactic radiosurgery manage metastases and improve quality of life for international patients.
Bookimed Expert Insight: Thailand ranks 4th globally for medical tourism on Bookimed due to high-capacity centers. Bumrungrad International Hospital alone treats 1,000,000 patients annually. While chemotherapy is standard, 50% of international patients seek Thailand for its rapid access to molecular testing. This testing is crucial as it determines if targeted drugs can replace traditional chemotherapy.
Patient Consensus: Patients emphasize that getting an EGFR or ALK mutation test first is vital. This step often reveals better drug options than standard chemotherapy. They also note that private centers in Bangkok provide significantly faster results for these critical diagnostic scans.
Stage 4 lung cancer is generally incurable in Thailand. Most medical teams manage it as a chronic condition. Thai oncology centers use molecular testing and targeted therapies to extend life. Some patients achieve survival markers of 5 years or more through personalized systemic treatments.
Bookimed Expert Insight: While stage 4 is complex, Bumrungrad International Hospital serves over 1 million patients annually. Their JCI-accredited facility utilizes robotic surgery and AI for precision diagnosis. This high patient volume often leads to faster access to molecular testing results compared to smaller regional centers. This speed is vital for starting the correct targeted therapy immediately.
Patient Consensus: Patients emphasize that focusing on symptom control and genetic testing is crucial. Many suggest integrating palliative care early to maintain comfort and a better quality of life during systemic therapy.
Certified Thai centers offer foreign patients rapid access to advanced molecular testing. Facilities like Bumrungrad International Hospital maintain Joint Commission International (JCI) accreditation. They use PET-CT scans and robotic systems to manage advanced cases. These centers specialize in multidisciplinary care for stage 4 patients.
Bookimed Expert Insight: Thailand ranks 4th globally in medical travel for a specific reason. Our data shows centers like Bumrungrad employ 1,300 doctors across 70 departments. These hospitals operate like small cities to eliminate delays. Stage 4 patients avoid waiting weeks for biopsy reviews found elsewhere. This speed allows treatment to start almost immediately upon arrival.
Patient Consensus: Patients value how smoothly international desks handle records and scheduling. They often note that the seamless coordination reduces the stress of navigating complex care.
Biomarker testing in Thailand directs stage 4 lung cancer treatment by identifying mutations like EGFR, ALK, and ROS1. This precision approach allows Thai oncologists to prescribe targeted therapies instead of standard chemotherapy. Testing occurs at diagnosis to ensure patients receive the most effective first-line drugs.
Bookimed Expert Insight: Thai medical centers handle high international volumes, with Bumrungrad International Hospital alone serving over 1 million patients annually. Their oncology teams utilize integrated digital pathology to speed up biomarker interpretation. This allows patients from 190 countries to start targeted therapies much faster than in many regional centers.
Patient Consensus: Patients emphasize that waiting for full biomarker results is better than starting the wrong treatment. They recommend requesting a broad molecular panel immediately to avoid wasting limited biopsy tissue on single-gene tests.